Intellia Therapeutics (NTLA) Competitors

Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Which has more volatility & risk, NTLA or BEAM?

Intellia Therapeutics has a beta of 2.31, meaning that its share price is 131% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.

Do analysts prefer NTLA or BEAM?

Intellia Therapeutics currently has a consensus target price of $29.05, suggesting a potential upside of 164.11%. Beam Therapeutics has a consensus target price of $48.45, suggesting a potential upside of 176.57%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.58
Beam Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.07

Does the media refer more to NTLA or BEAM?

In the previous week, Intellia Therapeutics had 3 more articles in the media than Beam Therapeutics. MarketBeat recorded 27 mentions for Intellia Therapeutics and 24 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.26 beat Intellia Therapeutics' score of 0.24 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better valuation and earnings, NTLA or BEAM?

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$52.86M	21.56	-$519.02M	-$4.69	-2.35
Beam Therapeutics	$60.27M	29.41	-$376.74M	-$4.50	-3.89

Do institutionals & insiders have more ownership in NTLA or BEAM?

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.5% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is NTLA or BEAM more profitable?

Beam Therapeutics has a net margin of -661.31% compared to Intellia Therapeutics' net margin of -908.48%. Beam Therapeutics' return on equity of -43.15% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-908.48%	-57.48%	-45.04%
Beam Therapeutics	-661.31%	-43.15%	-31.06%

Summary

Beam Therapeutics beats Intellia Therapeutics on 13 of the 17 factors compared between the two stocks.